7 withdrawn. 7 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Withdrawn 7 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Opioid Use Disorder: new trials by email Literature Review of Opioid Use Disorder trials Research Report on Opioid Use Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder Psilocybin - Opioid Use Disorder | Phase 2 | Withdrawn | Johns Hopkins University | 2027-04-01 | 2026-02-23 | |
| Sublingual Buprenorphine Through Telemedicine vs In-Person Care as Usual Buprenorphine SL, Telehealth, In-person treatment as usual - Opioid Use Disorder | Phase 2 | Withdrawn | New York State Psychiatric Institute | 2026-06-01 | 2026-09-08 | |
| Psilocybin for Opioid Use Disorder in Patients on Methadone Maintenance With Ongoing Opioid Use Placebo, Psilocybin - Opioid Use Disorder | Phase 2 | Withdrawn | Johns Hopkins University | 2023-12-01 | 2024-02-02 | |
| Olanzapine in OUD Patients Olanzapine - Opioid Use Disorder | Phase 2 | Withdrawn | University of Pennsylvania | 2022-07-28 | 2023-02-01 | |
| Combined Injectable Treatment for HIV and OUD Combined LAI Treatment: Cabenuva and Sublocade - Human Immunodeficiency Virus, Opioid Use Disorder | Phase 2 | Withdrawn | Rhode Island Hospital | 2022-04-01 | 2026-02-18 | |
| A Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants With Opioid Use Disorder ASP8062, Placebo ASP8062, buprenorphine/naloxone - Opioid Use Disorder | Phase 2 | Withdrawn | Astellas Pharma Global Development, Inc. | 2021-11-08 | 2024-11-06 | |
| NT-814: Evaluation of Its Ability to Alter the Abuse Liability of Oxycodone in an Exploratory Clinical Study Placebo, NT-814 50 mg, NT-814 100 mg - Opioid Use Disorder | Phase 1 / Phase 2 | Withdrawn | New York State Psychiatric Institute | 2016-02-01 | 2020-08-04 |
Opioid-Related Disorders (7) · Acquired Immunodeficiency Syndrome (1)
Chemically-Induced Disorders (7) · Mental Disorders (7) · Narcotic-Related Disorders (7) · Substance-Related Disorders (7) · Blood-Borne Infections (1) · Communicable Diseases (1) · Genital Diseases (1) · HIV Infections (1) · Immune System Diseases (1) · Immunologic Deficiency Syndromes (1) · Infections (1) · Lentivirus Infections (1) · RNA Virus Infections (1) · Retroviridae Infections (1) · Sexually Transmitted Diseases (1)
Psilocybin (2) · ASP8062 (1) · Buprenorphine (1) · Buprenorphine, Naloxone Drug Combination (1) · Olanzapine (1) · Rilpivirine (1) · Sublocade (1) · Telemedicine (1) · cabotegravir, rilpivirine drug combination (1)
Johns Hopkins University (2) · New York State Psychiatric Institute (2) · Astellas Pharma Global Development, Inc. (1) · Rhode Island Hospital (1) · University of Pennsylvania (1)
United States (4)
Albert Arias, MD (1) · Anna Rose Childress, PhD (1) · Christina Brezing, MD (1) · Gerard Moeller, MD (1) · Josiah D Rich, MD (1) · Kyle Kampman, MD (1) · Matthew W Johnson, PhD (1) · Sandeep Nayak, MD (1) · Sandra D Comer, PhD (1)
R21DA055835 (1), U54DA037842 (1)